The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases
Open accessAbstract
Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels. Individual contributing factors have been the focus of extensive research. As part of the Integrative Human Microbiome Project (HMP2 or iHMP), we followed 132 subjects for one year each to generate integrated longitudinal molecular profiles of host and microbial activity during disease (up to 24 time points each; in total 2,965 stool, biopsy, and blood specimens). Here we present the results, which provide a comprehensive view of functional dysbiosis in the gut microbiome during inflammatory bowel disease activity. We demonstrate a characteristic increase in facultative anaerobes at the expense of obligate anaerobes, as well as molecular disruptions in microbial transcription (for example, among clostridia), metabolite pools (acylcarnitines, bile acids, and short-chain fatty acids), and levels of antibodies in host serum. Periods of disease activity were also marked by increases in temporal variability, with characteristic taxonomic, functional, and biochemical shifts. Finally, integrative analysis identified microbial, biochemical, and host factors central to this dysregulation. The study’s infrastructure resources, results, and data, which are available through the Inflammatory Bowel Disease Multi’omics Database ( http://ibdmdb.org ), provide the most comprehensive description to date of host and microbial activities in inflammatory bowel diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This relative absence of biomarkers for active UC may result both from its generally more benign phenotype (IBDMDB Investigators et al., 2019) and from the smaller number of active UC samples (n = 23) compared with active CD samples (n = 76); as a result, we focused our subsequent analyses on expression differences within the CD subcohort.”
From Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 (2021) · cites this paper as IBDMDB Investigators et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This network of mechanistic associations identified several key components that are central to the alterations seen in IBD, highlighting octanoyl carnitine, several lipids and short-chain fatty acids, the taxa Faecalibacterium, Subdoligranulum, Roseburia, Alistipes, and Escherichia, some at both the metagenomic and metatranscriptomic levels, and host regulators of interleukins49.”
From The Integrative Human Microbiome Project (2019) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Multiple lines of evidence point towards central roles of gut microbiome perturbations in the pathogenesis of IBD.”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“These studies, which have now reached the first stage of completion49–51, together provide a wealth of information and insights about not only microbial dynamics, but also associated human host responses and microbial inter-relationships.”
From The Integrative Human Microbiome Project (2019) · cites this paper as [49]
In the citing paper
“The authors could then use the 17 top taxa in their ranked list to identify which individuals are dysbiotic, an approach that demonstrated similar or better performance than the GMWI2 or another published metric called the “dysbiotic score”.195”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [195]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationUPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Fast and sensitive protein alignment using DIAMOND
Buchfink, B., Xie, C., & Huson, D. H. (2015) · Nature Methods · doi:10.1038/nmeth.3176 · Cited by 14,201
Cited by
Items 801–900 of 1,010
Zhan, Q., Wang, R., Thakur, K., Feng, J.-Y., Zhu, Y.-Y., Zhang, J., & Wei, Z. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2138263 · Cited by 43
“There was a positive correlation between low fecal levels of B 2 and F. prausnitzii in a large multi-omics study in IBD patients (Lloyd-Price et al. 2019), suggesting that B 2 may support this prominent butyrate-producer and modulate the microbial dysbiosis in IBD.”
BackgroundGao, S., Gao, X., Zhu, R., Wu, D., Feng, Z., Jiao, N., Sun, R., Gao, W., He, Q., Liu, Z., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2221428 · Cited by 42
“Raw FASTQ files of 1241 fecal samples from four studies were downloaded from the European Nucleotide Archive (ENA) using the following identifiers: PRJNA398089 (D1) for Lloyd-Price et al.(9), PRJNA385949 (D2) for Hall et al.”
MethodTomofuji, Y., Kishikawa, T., Maeda, Y., Ogawa, K., Otake-Kasamoto, Y., Kawabata, S., Nii, T., Okuno, T., Oguro-Igashira, E., Kinoshita, M., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100219 · Cited by 35
Antimicrobial peptide production in response to gut microbiota imbalance
Cardoso, M. H. E. S., Meneguetti, B. T., Oliveira-Júnior, N. G., Macedo, M. L. R., & Franco, O. L. (2022) · Peptides · doi:10.1016/j.peptides.2022.170865 · Cited by 40
Lee, Y., Cappellato, M., & Camillo, B. D. (2022) · GigaScience · doi:10.1093/gigascience/giad083 · Cited by 45
Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption
Bhattarai, S. K., Du, M., Zeamer, A. L., Mortzfeld, B. M., Kellogg, T. D., Kaya, F., Benjamin, A., Bean, J. M., Zimmerman, M., Mardi, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi9711 · Cited by 44
Gut bacteriome in inflammatory bowel disease: An update on recent advances
Bajaj, A., Markandey, M., Kedia, S., & Ahuja, V. (2024) · Indian Journal of Gastroenterology · doi:10.1007/s12664-024-01541-1 · Cited by 45
“The compositional and functional alterations in gut microbiota, which marks the loss of beneficial gut microbiota and bloom of pathobionts, have been widely implicated in IBD [7, 8].”
Dong, F., Hao, L., Wang, L., & Huang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.064 · Cited by 41
Kim, H., Nelson, P., Nzabarushimana, É., Shen, J., Jensen, J., Bhosle, A., Li, C., Lee, N., Everett, C., Berdy, B. M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01318-6 · Cited by 41
“The observed increase in oral-typical microbes in MASLD, coupled with this enrichment of Streptococcus in non-lean MASLD, may suggest a link between disease subtypes and increased oral translocation to the gut, a characteristic feature of other chronic inflammatory conditions 16,25 .”
Self-citationPrecise probiotic therapy: Advances, bottlenecks, and the road to microbiome-informed nutrition
Jiang, Y., Jiang, S., Wang, Z., Zhu, P., Zhang, J., Teng, F., & Huang, S. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2623359 · Cited by 46
“61,62 At more advanced stages, predictive frameworks facilitate the selective application of strain-specific probiotic interventions to individuals most likely to respond, thereby mitigating disease progression and reducing inter-individual variability in outcomes.”
Rogala, A. R., Oka, A., & Sartor, R. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00214 · Cited by 39
“IBD and yet unknown functions being frequently described (51, 52, 59).”
BackgroundInfluentialAdvances in the understanding of the intestinal micro-environment and inflammatory bowel disease
Yan, P., & Li, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000718 · Cited by 36
“A large-scale longitudinal study applied corresponding meta-genomics, meta-transcriptomics, viromics, proteomics, and untargeted metabolomics during a 1-year follow-up of patients with IBD.([6]) Overall, although different functional profiles”
BackgroundEstimating scale-invariant directed dependence of bivariate distributions
Junker, R. R., Griessenberger, F., & Trutschnig, W. (2020) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2020.107058 · Cited by 47
“Moreover, analyzing networks via Pearson’s r or Spearman’s ρ inevitably leads to symmetric community structures and functional linkages between organisms or individuals and may complicate the understanding of microbial, biochemical and genetic causes for human diseases (see [27]).”
MethodEmerging Roles of Gut Virome in Pediatric Diseases
Fulci, V., Stronati, L., Cucchiara, S., Laudadio, I., & Carissimi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084127 · Cited by 40
“Recently, several groups carried out multi-omics research to comprehensively assess the composition of both the microbiome and the virome in the gut of pediatric [51,52] and adult IBD patients [25].”
BackgroundThänert, R., Thänert, A., Ou, J., Bajinting, A., Burnham, C. D., Engelstad, H. J., Tecos, M. E., Ndao, I. M., Hall-Moore, C. M., Rouggly-Nickless, C., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1940792 · Cited by 39
“Repeat measures permutational analysis of variance (PERMANOVA) was implemented taking advantage of a previously developed custom script.(39) Patient ID was included as a mandatory blocking factor in all repeat measure PERMANOVA.”
MethodSchierová, D., Roubalová, R., Kolář, M., Stehlíková, Z., Rob, F., Jackova, Z., Coufal, Š., Thon, T., Mihula, M., Modrák, M., et al. (2021) · Cells · doi:10.3390/cells10113188 · Cited by 43
“torques are associated with patients with IBD [50,51] and are reported to produce inflammatory polysaccharides [52], the true ruminococci from Ruminococcaceae family are enriched in HC [53,54] or associated with IFX responders [39,55].”
Backgroundm6A modification in inflammatory bowel disease provides new insights into clinical applications
Zhang, J., Song, B., Zeng, Y., Xu, C., Gao, L., Guo, Y., & Liu, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114298 · Cited by 34
Microbiota-directed biotherapeutics: considerations for quality and functional assessment
Fekete, E. E. F., Figeys, D., & Zhang, X. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186671 · Cited by 38
Lee, D. H., Seong, H., Chang, D., Gupta, V. K., Kim, J., Cheon, S., Kim, G., Sung, J., & Han, N. S. (2023) · npj Science of Food · doi:10.1038/s41538-023-00195-1 · Cited by 39
The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy
Yuan, S., Wang, K.-S., Meng, H., Hou, X.-T., Xue, J.-C., Liu, B., Cheng, W., Li, J., Zhang, H., Nan, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114893 · Cited by 37
The metabolomic physics of complex diseases
Wu, S., Liu, X., Dong, A., Gragnoli, C., Griffin, C. H., Wu, J., Yau, S., & Wu, R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308496120 · Cited by 38
“As a recent focus of medical research, we still know little about the physiological mechanisms underlying the difference and commonality between CD and UC (33, 35).”
Loss of claudin-3 expression increases colitis risk by promoting Gut Dysbiosis
Ahmad, R., Kumar, B., Thapa, I., Talmon, G. A., Salomon, J., Ramer‐Tait, A. E., Bastola, D. K., Dhawan, P., & Singh, A. B. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2282789 · Cited by 38
“37 On the other hand, Bifidobacterium and Dubosiella which are low in Cldn3 KO mice associate negatively with IL-6, STAT3, and NFkB expression.”
BackgroundMethodInfluentialLiu, M., Chen, J., Dharmasiddhi, I. P. W., Chen, S., Liu, Y., & Liu, H. (2024) · Processes · doi:10.3390/pr12020316 · Cited by 42
Mucin Expression Profiles in Ulcerative Colitis: New Insights on the Histological Mucosal Healing
Leoncini, G., Cari, L., Ronchetti, S., Donato, F., Caruso, L., Calafà, C., & Villanacci, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031858 · Cited by 35
“Transcriptomics data were downloaded from the Inflammatory Bowel Disease Multi’omics Database (IBDMDB) [45].”
MethodThe gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever
Silverman, G. J., Azzouz, D. F., Gisch, N., & Amarnani, A. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01071-8 · Cited by 41
“Gut expansions of R. gnavus have been described in patients with SLE, as well as other autoimmune and inflammatory diseases, and were first described in patients with irritable bowel disease (IBD) 112–116 , including Crohn’s disease.”
Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis
Bernardi, F., D’Amico, F., Bencardino, S., Faggiani, I., Fanizza, J., Zilli, A., Parigi, T. L., Allocca, M., Danese, S., & Furfaro, F. (2024) · Pharmaceuticals · doi:10.3390/ph17030347 · Cited by 41
“Also, dysbiosis involves an increase in Proteobacteria and Fusobacteria and a decrease in various phyla, notably Firmicutes, including Clostridiales [74].”
BackgroundWang, S., Guan, C., Wang, P., Wang, D., Wang, H., Yip, R. C. S., & Chen, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133395 · Cited by 35
Li, X., Xia, X. L., Wang, S., Wu, B., Zhou, Y., & Deng, P. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2464225 · Cited by 44
Liu, Y., Li, X., Chen, Y., Yao, Q., Zhou, J., Wang, X., Meng, Q., Ji, J., Yu, Z., & Chen, X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1556827 · Cited by 52
Imbalance in gut microbial interactions as a marker of health and disease
López, R. C., Bonachela, J. A., Dominguez-Bello, M. G., Manhart, M., Levin, S. A., Blaser, M. J., & Muñoz, M. A. (2026) · Science · doi:10.1126/science.ady1729 · Cited by 51
Epigenome-metabolome-microbiome axis in health and IBD
Amatullah, H., & Jeffrey, K. L. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.08.005 · Cited by 38
Determinants of Staphylococcus aureus carriage in the developing infant nasal microbiome
Accorsi, E. K., Franzosa, E. A., Hsu, T. Y., Cordy, R. J., Maayan‐Metzger, A., Jaber, H., Reiss-Mandel, A., Kline, M. C., DuLong, C. R., Lipsitch, M., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02209-7 · Cited by 34
“Whole-genome fragment libraries were prepared as follows at the Broad Institute [87].”
MethodInfluentialSelf-citationOral Microbiome Analysis in Prospective Genome Cohort Studies of the Tohoku Medical Megabank Project
Saito, S., Aoki, Y., Tamahara, T., Goto, M., Matsui, H., Kawashima, J., Danjoh, I., Hozawa, A., Kuriyama, S., Suzuki, Y., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.604596 · Cited by 35
“, 2019) and inflammatory bowel disease (Lloyd-Price et al., 2019), and preterm birth (Fettweis et al.”
BackgroundSarrabayrouse, G., Elías, A. D., Yáñez, F., Mayorga, L., Varela, E., Bartoli, C., Casellas, F., Borruel, N., Guise, C. H.-D., Machiels, K., et al. (2021) · mSystems · doi:10.1128/msystems.01277-20 · Cited by 37
Biosensors for point-of-care testing and personalized monitoring of gastrointestinal microbiota
Ngashangva, L., & Chattopadhyay, S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1114707 · Cited by 38
Autoimmune diseases exhibit shared alterations in the gut microbiota
Wang, T., Sternes, P. R., Guo, X.-K., Zhao, H., Xu, C., & Xu, H. (2023) · Rheumatology · doi:10.1093/rheumatology/kead364 · Cited by 47
“Previous studies have shown that IPA was significantly depleted in the metabolic profile of an IBD cohort, indicating that IPA may also play an important role in human enteritis [33].”
ResultMannion, A. J., Sheh, A., Shen, Z., Dzink-Fox, J., Piazuelo, M. B., Wilson, K. T., Peek, R. M., & Fox, J. G. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186677 · Cited by 36
Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase‐Like to Catalase‐Like Activity
Kim, H. S., Lee, S., & Lee, D. Y. (2023) · Small · doi:10.1002/smll.202302331 · Cited by 36
Zou, F., Wang, S., Xu, M., Wu, Z., & Deng, F. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1235656 · Cited by 42
Allegretti, J. R., Khanna, S., Mullish, B. H., & Feuerstadt, P. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.004 · Cited by 37
Deek, R. A., Ma, S., Lewis, J., & Li, H. (2024) · eLife · doi:10.7554/elife.88956 · Cited by 38
Yan, L., Wang, X., Yu, T., Qi, Z., Li, H., Nan, H., Wang, K., Luo, D., Hua, F., & Wang, W. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1367325 · Cited by 34
Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease
Bao, L.-L., Yu, Y., González-Acera, M., Patankar, J. V., Gießl, A., Sturm, G., Kühl, A. A., Atreya, R. N., Erkert, L., Gámez‐Belmonte, R., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn8699 · Cited by 40
Turpin, W., Lee, S.-H., & Croitoru, K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.01.004 · Cited by 37
Elmassry, M. M., Sugihara, K., Chankhamjon, P., Kim, Y., Camacho, F. R., Wang, S., Sugimoto, Y., Chatterjee, S., Chen, L. A., Kamada, N., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.01.002 · Cited by 39
Gut microbiota therapy in gastrointestinal diseases
Ullah, H., Arbab, S., Chang, C., Bibi, S., Muhammad, N., Rehman, S. U., Suleman, S., Ullah, I., Hassan, I. U., Tian, Y., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1514636 · Cited by 41
Multi‐Omics Signatures of Periodontitis and Periodontal Therapy on the Oral and Gut Microbiome
Baima, G., Dabdoub, S. M., Thumbigere‐Math, V., Ribaldone, D. G., Caviglia, G. P., Tenori, L., Fantato, L., Vignoli, A., Romandini, M., Ferrocino, I., et al. (2025) · Journal of Periodontal Research · doi:10.1111/jre.70055 · Cited by 36
“This temporal lag is consistent with prior studies showing that mucosal metabolomes, being the integrated product of both microbiota and host factors, tend to be highly resilient [66, 75].”
The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps
Sutherland, V. L., McQueen, C. A., Mendrick, D. L., Gulezian, D., Cerniglia, C. E., Foley, S. L., Forry, S., Khare, S., Liang, X., Manautou, J. E., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa060 · Cited by 33
“Understanding the functions, features and normal ranges of the microbial communities that support health will be essential in addressing impacts of environmental agents and potentially identifying microbial configurations that result in disease (Lloyd-Price et al., 2016, 2019).”
BackgroundA Comparative Evaluation of Tools to Predict Metabolite Profiles From Microbiome Sequencing Data
Yin, X., Altman, T., Rutherford, E. M., West, K., Wu, Y., Choi, J., Beck, P. L., Kaplan, G. G., Dabbagh, K., DeSantis, T. Z., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.595910 · Cited by 35
“For differential metabolite prediction, we first identified differential microbial functions (KOs/RXNs) between case and control samples via DESeq2 analysis (adjusted p-value threshold = 0.2; Love et al., 2014) following prevalence filtering at 5%.”
MethodInfluentialOwagboriaye, F. O., Mesnage, R., Dedeke, G. A., Adegboyega, T., Aladesida, A. A., Adeleke, M. T., Owa, S. O., & Antoniou, M. N. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.03.021 · Cited by 34
“approaches such as metabolomics or meta-transcriptomics could provide insight into functional aspects of the microbiome [46,47].”
BackgroundImmunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases
Selin, K., Hedin, C. R. H., & Villablanca, E. J. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab085 · Cited by 38
Fecal microbiome and bile acid metabolome in adult short bowel syndrome
Boutte, H. J., Chen, J., Wylie, T. N., Wylie, K. M., Xie, Y., Geisman, M., Prabu, A., Gazit, V., Tarr, P. I., Levin, M. S., et al. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00091.2021 · Cited by 33
Dąbek, A., Kaczmarczyk, O., Woźniakiewicz, M., Paśko, P., Dobrowolska‐Iwanek, J., Woźniakiewicz, A., Piątek-Guziewicz, A., Zagrodzki, P., & Zwolinska-Wcislo, M. M. (2022) · Biology · doi:10.3390/biology11010108 · Cited by 35
Multi-omics reveals microbiome, host gene expression, and immune landscape in gastric carcinogenesis
Park, C. H., Hong, C., Lee, A.-R., Sung, J., & Hwang, T. H. (2022) · iScience · doi:10.1016/j.isci.2022.103956 · Cited by 39
“Moreover, recent multi-omic studies have provided striking revelations underlying biomolecular mechanisms underlying human diseases (Lee et al., 2021; Lloyd-Price et al., 2019; Su et al., 2020; Tong et al., 2016).”
BackgroundHolistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
Sudhakar, P., Wellens, J., Verstockt, B., Ferrante, M., Sabino, J., & Vermeire, S. (2022) · Gut · doi:10.1136/gutjnl-2022-328221 · Cited by 38
Metabolic engineering of human gut microbiome: Recent developments and future perspectives
Li, P., Roos, S., Luo, H., Ji, B., & Nielsen, J. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2023.06.006 · Cited by 37
Metabolic independence drives gut microbial colonization and resilience in health and diseasePreprint
Watson, A. R., Füssel, J., Veseli, I., DeLongchamp, J. Z., Silva, M., Trigodet, F., Lolans, K., Shaiber, A., Fogarty, E. C., Runde, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.02.433653 · Cited by 34
Kang, Y. H., Tucker, S. A., Quevedo, S. F., Inal, A., Korzenik, J. R., & Haigis, M. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273080 · Cited by 33
Carr, R. M., Li, Y., Chau, L., Friedman, E. S., Lee, J., Adorini, L., Erickson, M., Zaru, L., Shringarpure, R., MacConell, L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000474 · Cited by 36
“Two of these were used in analyses of the gut microbiome and have been previously published, the Human Micro-biome Project 2 (HMP2) [29] and the “ Single dose and multiple dose trial to assess pharmacokinetics of obeticholic acid ” (747-105).”
MethodZha, A., Tu, R., Qi, M., Wang, J., Tan, B., Liao, P., Wu, C., & Yin, Y. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115448 · Cited by 39
MetaTransformer: deep metagenomic sequencing read classification using self-attention models
Wichmann, A., Buschong, E., Müller, A., Jünger, D., Hildebrandt, A., Hankeln, T., & Schmidt, B. (2023) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqad082 · Cited by 40
“To demonstrate the applicability of our approach, we analyzed a real-world metagenomic gut dataset with focus on IBD ( 39 ).”
MethodResultInfluentialAdenosine in Intestinal Epithelial Barrier Function
Stepanova, M., & Aherne, C. M. (2024) · Cells · doi:10.3390/cells13050381 · Cited by 35
Sun, J., Chen, M., Hu, Z., Xu, N., Wang, W., Ping, Z., Zhu, J., Sun, D., Zhu, Z., Li, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50223-1 · Cited by 45
Gut redox and microbiome: charting the roadmap to T-cell regulation
Prasad, S., Singh, S., Menge, S., Mohapatra, I., Kim, S., Helland, L. C., Singh, G., & Singh, A. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1387903 · Cited by 38
Host–pathobiont interactions in Crohn’s disease
Caruso, R., Lo, B. C., Chen, G., & Núñez, G. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00997-y · Cited by 44
“R. torques , a species abundant in patients with Crohn’s disease 125 , is the most important taxon associated with Crohn’s disease risk 135 .”
InfluentialReal-world of Limosilactobacillus reuteri in mitigation of acute experimental colitis
Yue, N., Zhao, H., Hu, P., Zhang, Y., Tian, C., Chen, K., Mai, Z., Huang, L., Luo, Q., Wei, D., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03158-8 · Cited by 35
Bioactivity and biomedical applications of pomegranate peel extract: a comprehensive review
Du, J., Wang, H., Zhong, L., Wei, S., Min, X., Deng, H., Zhang, X., Zhong, M., & Huang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1569141 · Cited by 43
Bespoke plant glycoconjugates for gut microbiota–mediated drug targeting
Ma, W. J., Wang, C., Kothandapani, J., Luzentales-Simpson, M., Menzies, S. C., Bescucci, D. M., Lange, M., Fraser, A. S. C., Gusse, J. F., House, K. E., et al. (2025) · Science · doi:10.1126/science.adk7633 · Cited by 35
Xian, F., Brenek, M., Krisp, C., Urbauer, E., Kumar, R. R., Aguanno, D., Srikumar, T., Liu, Q., Barry, A. M., Ma, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61977-7 · Cited by 40
“The mutual relationship between the microbiome and the host is essential for maintaining intestinal homeostasis, and its disruption plays a role in the onset and progression of diseases, including in fl ammatory bowel diseases (IBD) 23,24 .”
InfluentialLiu, W., Tang, S., Zhao, Q., Zhang, W., Li, K., Yao, W., & Gao, X. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.303 · Cited by 35
What’s new in IBD therapy: An “omics network” approach
Fiocchi, C., & Iliopoulos, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104886 · Cited by 34
Wijdeveld, M., Nieuwdorp, M., & IJzerman, R. G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1761958 · Cited by 34
“absence of disease [164,165] and remains, for the major part, still unexplained [166,167].”
BackgroundGestational age-dependent development of the neonatal metabolome
Ernst, M., Rogers, S., Lausten‐Thomsen, U., Björkbom, A., Laursen, S. S., Courraud, J., Børglum, A. D., Nordentoft, M., Werge, T. M., Mortensen, P. B., et al. (2020) · Pediatric Research · doi:10.1038/s41390-020-01149-z · Cited by 38
He, X., Gao, J., Peng, L., Hu, T., Wan, Y., Zhou, M., Zhen, P., & Cao, H. (2020) · Gut · doi:10.1136/gutjnl-2020-322468 · Cited by 33
Wiendl, M., Becker, E. M., Müller, T. M., Voskens, C., Neurath, M. F., & Zundler, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656452 · Cited by 40
MiR-1-3p and MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon
Sun, T., Li, Y., Zhao, F., Sun, H., Gao, Y., Wu, B., Yang, S., Ji, F., & Zhou, D. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab179 · Cited by 38
Nieves, K., Hirota, S. A., & Flannigan, K. L. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00160.2021 · Cited by 36
Progress and opportunities in microbial community metabolomics
Bhosle, A., Wang, Y., Franzosa, E. A., & Huttenhower, C. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102195 · Cited by 36
Self-citationYin, M., Chen, Y., Liu, X., Tian, S., Zhao, L., Bai, Y., Wang, H., Lin, J., Jiang, D., Lei, Z., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12154 · Cited by 34
An integrated Bayesian framework for multi‐omics prediction and classification
Mallick, H., Porwal, A., Saha, S., Basak, P., Svetnik, V., & Paul, E. (2023) · Statistics in Medicine · doi:10.1002/sim.9953 · Cited by 40
“Further, it is not possible to use BART without non-trivial modifications to handle the increasingly common longitudinal nature of modern multi-omics studies, often entangled with multiple covariates and a mixture of cross-sectional and longitudinal data components across layers 16 .”
BackgroundMethodInfluentialSelf-citationZhong, Y., Fan, W., Meng, X., & Zhou, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1297240 · Cited by 37
“A disturbance in the gut microbiota (GM) balance can lead to the loss of multiple functions, such as the destruction of barrier function, disorders of in fl ammation, and immune function, resulting in the induction of diseases (6 – 8).”
BackgroundWirbel, J., Zych, K., Essex, M., Karcher, N., Kartal, E., Salazar, G., Peer Bork, B., Sunagawa, S., & Zeller, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.06.931808 · Cited by 33
“For training of ML models, we blocked repeated measurements for the same individual when applicable [27,28,30]; specifically for the iHMP dataset [30], we also subsampled the dataset to five repeated measurements per individual to avoid biases associated with differences in the number of samples per individual.”
BackgroundMethodResultInfluentialPereira‐Marques, J., Ferreira, R. M., & Figueiredo, C. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2323235 · Cited by 37
Hong, J., Fu, T., Liu, W., Du, Y., Bu, J., Wei, G., Yu, M., Lin, Y., Min, C., & Lin, D. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s456173 · Cited by 36
“13 There was also an enhancement of proteobacteria, Neisseriacaea corrodens, Pasteurellaceae, Veillonella parvula and E. coli in patients with CD. 14 Yeast and fungal taxa have also increased in CD patients such as Cyberlindnera jadinii, Clavispora lusitaniae, Candida albicans, Saccharomyces cerevisiae and Kluyveromyc…”
BackgroundInfluentialA metagenomics pipeline reveals insertion sequence-driven evolution of the microbiota
Kirsch, J. M., Hryckowian, A. J., & Duerkop, B. A. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.03.005 · Cited by 32
Qiao, Y., Tang, X., Liu, Z., Ocansey, D. K. W., Zhou, M., Shang, A., & Mao, F. (2024) · Pharmaceuticals · doi:10.3390/ph17050607 · Cited by 35
Absolute quantification of prokaryotes in the microbiome by 16S rRNA qPCR or ddPCR
Doyle, B., Reynolds, G. Z. M., Dvorak, M., Maghini, D. G., Natarajan, A., & Bhatt, A. S. (2025) · Nature Protocols · doi:10.1038/s41596-025-01165-5 · Cited by 39
“Repeat Steps 44–46 for the three subsequent dilution steps.”
Panelli, S., Epis, S., Cococcioni, L., Perini, M., Paroni, M., Bandi, C., Drago, L., & Zuccotti, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104962 · Cited by 33
Miao, F. (2021) · Nutrition · doi:10.1016/j.nut.2021.111579 · Cited by 35
Oral Microbiome of Crohn’s Disease Patients With and Without Oral Manifestations
Hu, S., Mok, J. S. R., Gowans, M., Ong, D. E. H., Hartono, J. L., & Lee, J. W. J. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac063 · Cited by 41
Coquant, G., Aguanno, D., Brot, L., Belloir, C., Delugeard, J., Roger, N., Pham, H., Briand, L. V., Moreau, M., Sordi, L. D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13451-3 · Cited by 32
Lê, A., Mantel, M., Marchix, J., Bodinier, M., Jan, G., & Rolli‐Derkinderen, M. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00002.2022 · Cited by 38
Nyström, N., Prast‐Nielsen, S., Correia, M. S. P., Globisch, D., Engstrand, L. G., Schuppe‐Koistinen, I., & Halfvarson, J. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac149 · Cited by 33
“5] Plasma samples, N 46 9 11 Ileal biopsies, N 35 8 10 Inflamed ileal biopsies, N 19 0 0 Colonic biopsies, N 45 8 10 Inflamed colonic biopsies, N 27 6 0 CD location L1 Ileal, N [%] 13 [28] L2 Colonic, N [%] 17 [36] L3 Ileocolonic, N [%] 17 [36] L4a Upper gastrointestinal disease, N [%] 12 [26] CD behaviour B1 Non-stri…”
Robust cross-cohort gut microbiome associations with COVID-19 severity
Li, J., Ghosh, T. S., MacCann, R., Mallon, P. W. G., Hill, C., Draper, L. A., Schult, D., Fanning, L. J., Shannon, R., Sadlier, C., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2242615 · Cited by 33
“Next, we quantified the degree of microbiome dysbiosis by classifying as ‘dysbiotic’ datasets with taxonomic compositions beyond the 90 percentile of the distribution in healthy controls, in accordance with the classification procedure proposed by.(38) Notably, the frequency of pooled shotgun metagenomes classified as…”
MethodPeña‐Cearra, A., Song, D., Castelo, J., Palacios, A., Lavín, J. L., Azkargorta, M., Elortza, F., Fuertes, M., Pascual‐Itoiz, M. Á., Barriales, D., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00443-y · Cited by 34
“An imbalance of the secondary bile acid pool was also observed in IBD patients with gut dysbiosis 7 .”
BackgroundRicciuto, A., Sherman, P. M., & Laxer, R. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108415 · Cited by 36
Michaels, M., & Madsen, K. L. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2022.11.001 · Cited by 36
Santiago, A., Hann, A., Constante, M., Rahmani, S., Libertucci, J., Jackson, K. J., Rueda, G. H., Rossi, L., Ramachandran, R., Ruf, W., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2205425 · Cited by 35
“characterized by a decrease in known beneficial bacteria such as Akkermansia muciniphila, Alistipes putredinis, and Ruminococcus bromii, previously shown to be reduced in IBD patients.(42,43) We also found that opportunistic pathogens were increased in CD-HPA colonized mice, such as Romboutsia ilealis, that has been r…”
BackgroundKey progresses of MOE key laboratory of macromolecular synthesis and functionalization in 2022
Deng, X., Chen, K., Pang, K., Liu, X., Gao, M., Ren, J., Yang, G., Wu, G., Zhang, C., Ni, X., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108861 · Cited by 29
Chen, Y., Han, B., Guan, X., Du, G., Sheng, B., Tang, X., Zhang, Q., Xie, H., Jiang, X., Tan, Q., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.09.008 · Cited by 32
“Moreover, SAA1 has been shown to be associated with gut microbial ecology and inflammation in recent years [74,75].”
Background
Metadata
- Authors
- Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., Casero, D., Courtney, H., Gonzalez, A., Graeber, T. G., Hall, A. B., Lake, K., Landers, C. J., Mallick, H., Plichta, D. R., Prasad, M., Rahnavard, G., Sauk, J., Shungin, D., Vázquez-Baeza, Y., White, R. A., IBDMDB Investigators, Bishai, J., Bullock, K., Deik, A., Dennis, C., Kaplan, J. L., Khalili, H., McIver, L. J., Moran, C. J., Nguyen, L., Pierce, K. A., Schwager, R., Sirota-Madi, A., Stevens, B. W., Tan, W., ten Hoeve, J. J., Weingart, G., Wilson, R. G., Yajnik, V., Braun, J., Denson, L. A., Jansson, J. K., Knight, R., Kugathasan, S., McGovern, D. P. B., Petrosino, J. F., Stappenbeck, T. S., Winter, H. S., Clish, C. B., Franzosa, E. A., Vlamakis, H., Xavier, R. J., & Huttenhower, C.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Pacific Northwest National Laboratory (US)
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Cedars-Sinai Medical Center (US)
- Emory University (US)
- University of California San Diego (US)
- Washington University in St. Louis (US)
- Corresponding author
- Huttenhower, Curtis
- ORCID
- Arze, Cesar
- Ananthakrishnan, Ashwin N.
- Schirmer, Melanie
- Ajami, Nadim J.
- Bonham, Kevin S.
- Brislawn, Colin J.
- Casero, David
- Graeber, Thomas G.
- Hall, A. Brantley
- Mallick, Himel
- Plichta, Damian R.
- Sauk, Jenny
- Shungin, Dmitry
- Bullock, Kevin
- Deik, Amy
- Khalili, Hamed
- McIver, Lauren J.
- Nguyen, Long
- Pierce, Kerry A.
- Yajnik, Vijay
- Knight, Rob
- McGovern, Dermot P. B.
- Winter, Harland S.
- Clish, Clary B.
- Franzosa, Eric A.
- Vlamakis, Hera
- Xavier, Ramnik J.
- Huttenhower, Curtis
- Venue
- Nature
- Published
- 2019-05-29
- Volume
- 569
- Issue
- 7758
- Pages
- 655-662
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6650278
- OpenAlex
- W2947189704
- Cited by
- 3,143
- References
- 101
- Citations by year
- 2026: 500 · 2025: 555 · 2024: 498 · 2023: 402 · 2022: 441 · 2021: 452 · 2020: 247 · 2019: 42
- FWCI
- 98.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Science Foundation (1053486, DEAC05–76RL01830, 76RL01830)
- U.S. Department of Energy (DE-AC05–76RL01830, 76RL01830, AC05-76RL01830, DE-AC05?)
- Battelle (AC05-76RL01830, DE- AC05-76RL01830, DE-AC05)
- Leona M. and Harry B. Helmsley Charitable Trust (P01DK046763, U01DK062413)
- Harvard T.H. Chan School of Public Health
- Crohn's and Colitis Foundation (563526)
- Broad Institute
- Vetenskapsrådet (4.1-2016-00416)
- National Institutes of Health (DBI-1053486, UL1TR001881, DE-AC05-76RL01830)
- National Human Genome Research Institute (R01HG005969)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK046763, R24DK110499, U54DK102557, U01DK062413, P30DK078392, P30DK043351, P30DK040561)
- National Institute of Dental and Craniofacial Research (U54DE023798)
- National Center for Advancing Translational Sciences
- Army Research Office (W911NF-11-1-0473, W911NF, W911NF-11)
- Pacific Northwest National Laboratory (DEAC0576RL01830, 76RL01830)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- inflammatory bowel disease, Crohn's disease, ulcerative colitis, gut microbiota, dysbiosis, multi-omics, facultative anaerobes, obligate anaerobes, Clostridia, acylcarnitines, bile acids, short-chain fatty acids, serum antibodies, disease activity, temporal variation, host-microbe interactions
- MeSH terms
- Gastrointestinal Microbiome, Animals, Fungi, Health, Humans, Phylogeny, Species Specificity, Viruses, Inflammatory Bowel Diseases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.